Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 226

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 226
---
 working capital.

Although our management will assess the risks
inherent in a particular target business with which we may combine, we cannot assure you that this assessment will result in our identifying
all risks that a target business may encounter. Furthermore, some of those risks may be outside of our control, meaning that we can do
nothing to control or reduce the chances that those risks will adversely affect a target business.

We may seek to raise additional funds through
a private offering of debt or equity securities in connection with the completion of our initial business combination and we may effectuate
our initial business combination using the proceeds of such offering rather than using the amounts held in the Trust Account. In addition,
we intend to target businesses with enterprise values that are greater than we could acquire with the net proceeds of the IPO and the
sale of the private placement warrants, and, as a result, if the cash portion of the purchase price exceeds the amount available from
the Trust Account, net of amounts needed to satisfy any redemptions by public shareholders, we may be required to seek additional financing
to complete such proposed initial business combination. Subject to compliance with applicable securities laws, we would expect to complete
such financing only simultaneously with the completion of our initial business combination. In the case of an initial business combination
funded with assets other than the Trust Account assets, our proxy materials or tender offer documents disclosing the initial business
combination would disclose the terms of the financing and, only if required by law, we would seek shareholder approval of such financing.
There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances
or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop
agreements we may enter into following consummation of the IPO. Other than with respect to the Backup Agreement described above, (i) we
are not currently a party to any arrangement or understanding with any third party with respect to raising any additional funds through
the sale of securities or otherwise and (ii) none of our Sponsors, officers, directors or shareholders is required to provide any financing
to us in connection with or after our initial business combination.

9

Sources 

OmnigenicsAI was, and we anticipate that other
target business candidates will be, brought to our attention from various unaffiliated sources, including investment bankers and private
investment funds. Target businesses may be brought to our attention by such unaffiliated sources as a result of being